Based on in vitro studies, it is hypothesized that neurotrophic factor deprivation following deafferentation elicits an oxidative state change in the deafferented neuron and the formation of free radicals that then signal cell death pathways. This pathway to cell death was tested in vivo by assessing the efficacy of antioxidants (AOs) to prevent degeneration of deafferented CNVIII spiral ganglion cells (SGCs) in deafened guinea pigs. Following destruction of sensory cells, guinea pigs were treated immediately with Trolox (a water soluble vitamin E analogue) + ascorbic acid (vitamin C) administered either locally, directly in the inner ear, or systemically. Electrical auditory brainstem response (EABR) thresholds were recorded to assess nerve function and showed a large increase following deafness. In treated animals EABR thresholds decreased and surviving SGCs were increased significantly compared to untreated animals. These results indicate that a change in oxidative state following deafferentation plays a role in nerve cell death and antioxidant therapy may rescue SGCs from deafferentation-induced degeneration.
Introduction
The neurotrophic factor hypothesis (Mattson, 1998) suggests that with deafferentation of a neuron, neurotrophic factor deprivation leads to formation of reactive oxygen species (ROS) and a change in oxidant state (Dugan et al., 1997) . The formation of free radicals acts directly to destroy phospholipids and as signaling molecules to upregulate cell death pathways leading to apoptosis or necrosis (Davies, 1996; Greenlund et al., 1995; Deshmukh and Johnson, 1997, 1998; Van De Water et al., 2004) . The aim of this study was to test the hypothesis that a change in oxidative state and the formation of free radicals play an important role in deafferentation-induced cell death in vivo.
The auditory nerve is an excellent model to study interventions to prevent deafferentation-induced cell death, because it can be readily deafferented by destruction of cochlear hair cells, cochlear fluids allow introduction of test articles and there is a direct clinical relevance. The cochlear implant has provided remarkable benefits for patients with profound hearing impairment, however, its benefits depend upon the presence of a remaining excitable spiral ganglion cell (SGC) population (Pfingst, 1990; Kileny et al., 1991; Skinner et al., 1995; Blamey et al., 1996; Nadol et al., 1989, Incesulu and Nadol, 1998; Miller et al., 2000) . Loss of inner hair cells leads to a degeneration of denervated afferent CNVIII fibers and a loss of SGCs. The process begins with a rapid (days) degeneration of SGC peripheral processes followed by cell body degeneration and loss of the central axonal projection. In animal models the rate of degeneration can be rapid and profound, with > 50% loss of SGC in the ototoxically deafened guinea pig after 10 weeks (Yamagata et al., 2004) and 80% loss at 16 weeks post deafening (Jyung et al., 1989) . In humans, the process is much slower, extending over years, depending on the etiology of the inner ear pathology (Bergstrom, 1975; Otte et al., 1978; Nadol, 1997 Nadol, , 2001 .
Neurotrophic factors, including GDNF (glial cell line-derived neurotrophic factor), and BDNF (brainderived neurotrophic factor), can prevent SGC degeneration following loss of hair cells when provided by direct intracochlear infusion (Ylikoski et al., 1998 , Staecker et al., 1996 , Ernfors et al., 1996 , Miller et al., 1997 Shinohara et al., 2002; Yamagata et al., 2004) 
